Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Zebinix in Healthy Korean and Caucasian Adults
NCT04095182Phase 1Completed
- Sponsor
- WhanIn Pharm
- Start
- Aug 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of eslicarbazepine acetate in focal onset seizure (6 arms), sponsored by WhanIn Pharm. Primary endpoints: Time of maximum observed drug concentration at Day 11, Maximum observed plasma drug concentration at Day 11 and 5 more. Started Aug 2019; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT04095182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04095182.